Windgap Medical, Inc.
Windgap Medical is a privately-held pharmaceutical company focused on developing innovative drug delivery solutions that simplify, automate, and accelerate the administration of complex injectables. Their mission is to inject simplicity into complex drug delivery, improving patient experience and speeding time to market for new therapies. They design and deliver autoinjector platforms, including the wet/dry autoinjector platform and the compact ANDI® platform, to address unmet needs such as stability, portability, and ease of use. Windgap collaborates with pharmaceutical partners and has a strong focus on sustainability, reducing environmental impact through innovative technologies like lyophilized drug platforms and dual-chamber autoinjectors.
Industries
Nr. of Employees
small (1-50)
Windgap Medical, Inc.
200 Dexter Ave #270, Watertown, MA 02472
Patents
Compression seal for use with a liquid component storage vial of an auto-injector
US-11116903-B2
View Details
Compression seal for use with a liquid component storage vial of an auto-injector
US-11116903-B2
View DetailsProducts
Compact dual-chamber autoinjector (small-volume rescue)
Compact two-step dual-chamber autoinjector designed for automatic reconstitution and immediate injection of small-volume subcutaneous or intramuscular doses for lyophilized or liquid formulations.
Large-volume dual-chamber autoinjector platform
Gas-powered dual-cartridge autoinjector platform that automates reciprocating mixing and delivery for lyophilized or viscous liquid formulations, supporting larger volumes and high viscosities.
Compact dual-chamber autoinjector (small-volume rescue)
Compact two-step dual-chamber autoinjector designed for automatic reconstitution and immediate injection of small-volume subcutaneous or intramuscular doses for lyophilized or liquid formulations.
Large-volume dual-chamber autoinjector platform
Gas-powered dual-cartridge autoinjector platform that automates reciprocating mixing and delivery for lyophilized or viscous liquid formulations, supporting larger volumes and high viscosities.
Services
Partnership-based engineering programs to adapt platform architectures to specific formulations, viscosities, and dose volumes.
Collaborative feasibility and performance studies to evaluate mixing times, dissolution rates, delivery performance, and human factors for candidate formulations and device configurations.
Support for negotiating and executing licensing and commercialization partnerships to bring device-drug combination products to market.
Human factors engineering and design consultancy to simplify device workflows, reduce use-error risk, and support integration of device use into clinical programs.
Partnership-based engineering programs to adapt platform architectures to specific formulations, viscosities, and dose volumes.
Collaborative feasibility and performance studies to evaluate mixing times, dissolution rates, delivery performance, and human factors for candidate formulations and device configurations.
Support for negotiating and executing licensing and commercialization partnerships to bring device-drug combination products to market.
Human factors engineering and design consultancy to simplify device workflows, reduce use-error risk, and support integration of device use into clinical programs.
Expertise Areas
- Autoinjector device development
- Lyophilized (wet-dry) reconstitution systems
- High-viscosity injectable delivery
- Dual-chamber and sequential delivery systems
Key Technologies
- Dual-chamber autoinjector architectures
- Gas-driven reciprocating mixing mechanisms
- Side-by-side cartridge primary drug container design
- Closed septum-piercing fluidic connections
News & Updates
Windgap's strategic partnership with ALK-Abelló to commercialize its epinephrine autoinjector for the treatment of anaphylactic shock.
Windgap Medical's deal for a strategic investment from Molex Ventures, LLC, a subsidiary of Koch Industries.
Windgap Medical successfully completed its final close with over $39 million of Series B-1 equity financing.
Collaboration to design an autoinjector for cyanide antidote.
Windgap offers drug delivery devices that simplify, automate, and accelerate complex injectables.
Explores how Windgap’s gas power and side-by-side cartridge configuration increase the viscosity range for complex formulations.
Windgap's strategic partnership with ALK-Abelló to commercialize its epinephrine autoinjector for the treatment of anaphylactic shock.
Windgap Medical's deal for a strategic investment from Molex Ventures, LLC, a subsidiary of Koch Industries.
Windgap Medical successfully completed its final close with over $39 million of Series B-1 equity financing.
Collaboration to design an autoinjector for cyanide antidote.
Windgap offers drug delivery devices that simplify, automate, and accelerate complex injectables.
Explores how Windgap’s gas power and side-by-side cartridge configuration increase the viscosity range for complex formulations.